Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:7/29/2008

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of the clinical development program and regulatory strategy for picoplatin, the Company's lead product candidate.

* Oppenheimer & Co. Inc.'s Small & Mid Cap Clinical & Regulatory Conference on Monday, August 4, at 8:40 a.m. Eastern Time at the Oppenheimer office in New York. Mr. Martell will discuss Poniard's clinical development programs and regulatory strategy, and then participate in a subsequent panel discussion, entitled "Designing A Pivotal Program with an Eye Towards Approval." During this discussion, which begins at 9:55 a.m., Mr. Martell will discuss the regulatory path to approval for picoplatin.

* BMO Capital Markets' 2008 Focus on Healthcare Conference on Tuesday, August 5, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

A live audio webcast of each Poniard presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
2. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
3. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Announces Upcoming Conference Participation
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
10. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In ... Sciences a team of scientists in Guangzhou, China ... that expression of NR2F6 in patients with early cervical cancer ... patient,s cervical cancer tissue as well as in the normal ... an interesting study and the first that I am aware ...
(Date:12/7/2016)... Woods Hole, Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew ... 1966, Richard Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in ... to shore, where the turtle became a minor sensation because no one could remember ever ...
(Date:12/6/2016)... ... December 06, 2016 , ... Discovering new clues to natural treatments that ... what’s happening in our brains. And searching for keys to our immune systems by ... honored with the 2017 Edith and Peter O’Donnell Awards by The ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 ... of Santosh Kesari , MD, PhD, FANA, FAAN ... his experience in neurology and clinical trials to assist ... for treatment of stroke. The AmnioStem product is a universal ... previously shown therapeutic activity in animal models of stroke ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016 Not many of us realize that we spend ? of our ... need to do it well. Inadequate sleep levels have been found to lead to ... and even cancer. Maybe now is the best time to rethink how ... to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/29/2016)... 2016 Nearly one billion matches per second with ... ... DERMALOG is Germany's largest ... Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System ...
Breaking Biology News(10 mins):